Can-Fite Raises $4M via Warrant Exercise, Issues New Warrants
Event summary
- Can-Fite BioPharma exercised warrants for 1.59M ADSs at a reduced price of $2.50, raising ~$4M in gross proceeds.
- New warrants for 3.18M ADSs issued at $2.50 per ADS, exercisable for 24 months.
- Proceeds earmarked for R&D, clinical trials, and working capital.
- H.C. Wainwright & Co. acted as placement agent for the offering.
The big picture
Can-Fite’s warrant exercise and new issuance reflect a strategic move to bolster its cash position amid advanced-stage clinical trials. The $4M raise comes as the biotech navigates pivotal Phase 3 studies for its lead candidates, Piclidenoson and Namodenoson, in high-value markets like psoriasis and hepatocellular carcinoma. The transaction underscores the company’s focus on securing non-dilutive funding to extend its runway while avoiding equity dilution.
What we're watching
- Clinical Pipeline Progress
- How the $4M infusion will accelerate Can-Fite’s Phase 3 trials for Piclidenoson and Namodenoson.
- Execution Risk
- Whether Can-Fite can sustain momentum in its liver and inflammatory disease programs with the new capital.
- Market Dynamics
- The pace at which Can-Fite can translate clinical progress into commercial success in competitive therapeutic areas.
Related topics